-
Hear from a Global Fortune 500 CEO who is reimagining the ways his company uses innovative science, technology, and an “inspired, curious, unbossed” culture to deliver greater access to medicines.
-
-
Dr Enrica Alteri has extensive experience in drug discovery and clinical safety and worked at the European Medicines Agency for 8 years, serving on its Executive Board
-
Prof Jeffrey Skopek is Associate Professor of Law at the University of Cambridge and Deputy Director of its Centre for Law, Medicine and Life Sciences.
-
Join us on Nov 29 for a conversation with leaders from Novartis and Fortune on strategy, innovation, impact, and leadership, with learnings and advice relevant for all business leaders looking to advance equity.
-
Through a new collaboration with Beacon of Hope, Merck will operate clinical trials through four Historically Black Medical School clinical trial Centers of Excellence.
-
–Report Features New Disclosures of Company’s Impact on Planet—Including Scope 1, 2, and Select Scope 3 Greenhouse Gas (GHG) Emissions–
– Aligns with the Global Reporting Initiative (GRI) and Sustainability Accounting Standards Board (SASB) Reporting Frameworks –
-
More than 300 businesses across 51 industries and 29 countries have now joined The Climate Pledge and committed to pursue ambitious carbon-reduction activities across their business operations and supply chains
New signatories also include Climate Pledge Fund investees BETA Technologies, Infinium, and Pachama
-
Alnylam Issues 2021 Corporate Responsibility Report Wed, 03/16/2022 - 08:30 Type of Content Press Release Layout Featured Media Body – Report Features New Disclosures of Company’s Impact on Planet—Including Scope 1, 2, and Select Scope 3 Greenhouse Gas (GHG) Emissions –– Aligns with the Global Reporting Initiative (GRI) and Sustainability Accounting Standards Board (SASB) Reporting Frameworks – CAMBRIDGE, Mass., March 16, 2022 /3BL Media/ - Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leadi
-
The Energize program is a collaboration between 10 global pharmaceutical companies, including Novartis, to engage hundreds of suppliers in bold climate action and decarbonization of the pharmaceutical value chain.
-
-
Alcon associates across 43 global sites take the Steps for Sight challenge, raising funds to support organizations improving access to quality eye care
-
Alcon Geneva associates will dedicate the day to learning more about the importance of eye health, including onsite vision screenings and Alcon’s sight-enhancing surgical equipment and vision care products
-
Alcon Children’s Vision Program distributes free prescription eyeglasses to Fort Worth, Texas elementary school children, following prior vision screenings by Alcon volunteers
-
As the threat of resistance to current malaria treatment grows, Novartis and MMV have reported positive results of a new non-artemisinin combination in a Phase 2b study.
-
Novartis and children’s rights organization Save the Children are launching their first common health project tackling child mortality in Kenya's Kibera and Mathare slums.
-
Novartis and the Novartis US Foundation today announced a planned 10-year collaboration with Coursera, the National Medical Association, Thurgood Marshall College Fund, Morehouse School of Medicine and 26 additional Historically Black Colleges, Universities and Medical Schools (HBCUs)
-
Novartis and Hewlett Packard Enterprise (HPE) today announced a collaboration that aims to accelerate the use of data and digital technologies within Novartis efforts to reimagine global health and improve access to healthcare and medicines.
-
Novartis announced today that it has delivered one billion courses of antimalarial treatment since 1999. More than 90% of this artemisinin-based combination therapy (ACT) was supplied without profit to malaria-endemic countries around the globe.
-
Today, on World Water Day, Novartis inaugurated an integrated watershed development project to help address water scarcity in the Telangana region of India, one of the world’s most water-stressed countries.
-
Director of Clinical Trial Diversity Strategy nominated for her work promoting diversity and inclusion in the workplace and in clinical studies. SOURCE: Bristol Myers Squibb Company DESCRIPTION:Lorena Kuri, director, Clinical Trial Diversity Strategy, is among this year’s nominees for People en Español magazine’s list of most influential women. People en Español’s annual “Las 25 mujeres más poderosas” celebrates women who have made a difference empowering others. For 2021, the magazine called
-
Novartis today announced that it has entered into a grant agreement with the Bill & Melinda Gates Foundation. As part of the agreement, the foundation will provide funding support for the discovery and development of a single-administration, in vivo gene therapy to cure sickle cell disease (SCD).
-
SOURCE: Novartis SUMMARY:Project brings together Novartis drug discovery and gene therapy expertise and funding support from the Gates Foundation Agreement aims to address disparity in access to treatments and to prioritize populations and regions that bear the greatest burden of sickle cell disease in the search for curative therapies Effort expands on Novartis commitment to sickle cell disease, which includes a therapeutic pipeline and a holistic approach to diagnosis, treatment, and managemen
-
Novartis is building a leading focused medicines company powered by advanced therapy platforms and data science.
-
On 10 February, 4pm (GMT +1), hear from leading companies Novartis, L’Oréal and Credit Suisse about best practices to activate impactful Purpose initiatives to the benefit of employees, society, and their business.
-
A renewed partnership agreement signed by Novartis and the World Health Organization (WHO) will drive the global push towards making leprosy history. The five-year extension of the partnership – which was first signed in 2000 – will see Novartis continue to donate multidrug therapy (MDT) medicines to treat leprosy up to the end of 2025.
-
Novartis and GSK today announced the launch of a collaboration to support high-quality scientific research investigating the link between genetic diversity across different regions in Africa and its potential impact on response to drug therapeutics.
-
Leaders and clinical improvers gather virtually to share new ideas and evidence-based approaches to improve population health and health equity
-
Novartis today announced the signature of five virtual power purchase agreements (VPPAs), which are expected to collectively add more than 275 megawatts of clean power to the electrical grid.
-
New results from the largest ever research program on combining contact tracing with prophylactic treatment indicate this approach could massively reduce the global burden of leprosy.
-
Wilmington Protest, Wed., Oct. 14th - 12 noon – 1:00 pm ET
Dozens of concerned healthcare advocates from across the northeast region protest AstraZeneca, one of five U.S. based pharmaceutical companies that have cut back on the number of drugs they provide through the 340B federal drug discount program
-
Dozens of concerned healthcare advocates from across the northeast region protest AstraZeneca, one of five U.S. based pharmaceutical companies that have cut back on the number of drugs they provide through the 340B federal drug discount program.
-
-
Ongoing donation efforts deliver equipment and medical supplies needed for increasingly important eye care services and procedures to help underserved patients during the pandemic
-
Associates around the world participate in the Steps for Sight Challenge to help improve access to quality eye care
-
New Alcon Foundation video PSA highlights the importance of eye health screenings, premiering at this year’s American Academy of Optometry (AAO) annual meeting
-
OLON announced it will continue its collaboration with Novartis to support the Africa Sickle Cell Disease program as it expands to Kenya, Uganda and Tanzania.
-
-
SOURCE: Novartis DESCRIPTION:September 30, 2020 /3BL Media/ - COVID-19’s existence anywhere poses a threat to communities everywhere. The health, social, and economic impacts can only be addressed through the collective actions of stakeholders across private, public, and philanthropic sectors in partnership with civil society. As organizations dedicated to improving and protecting global health, with our varied skills, roles, and resources, we remain committed to doing our part in ending this pan
-
Today the Novartis US Foundation announced a total commitment of USD 25 million to develop partnerships and fund community organizations and programs that address health inequities, with a focus on diversity in clinical trials, in the United States
-
Novartis today announced the pricing of a [EUR 1.85] billion sustainability-linked bond (SLB), reinforcing its commitment to ESG principles and the 2025 Patient Access Targets announced earlier this month.
-
Low- and middle-income countries could soon leapfrog high-income countries in their adoption of new AI-enabled technologies in health, suggests a report led by the Novartis Foundation and Microsoft.
-
Novartis and the African Union (AU) through the Africa Medical Supplies Platform (AMSP) have announced a new collaboration to facilitate the supply of medicines from the Novartis Pandemic Response Portfolio to the AU member states and Caricom countries.
-
Novartis will host a virtual investor event today to provide a comprehensive overview of the company’s progress in its Environmental, Social and Governance (ESG) strategy.
-
Novartis announced a new initiative to help patients in low-income and lower-middle-income countries access affordable medicines to treat the major symptoms of COVID-19 – a critical need in the absence of a vaccine or curative treatment.
-
Novartis a annoncé, aujourd’hui, une nouvelle initiative visant à donner accès aux patients de pays à faibles revenus et à revenus intermédiaires (PFR; PRI) à des médicaments abordables pour traiter les principaux symptômes du COVID-19 – un besoin qui s’avère crucial en l’absence de vaccin ou de traitement curatif.
-
L'American Cancer Society (ACS) et la Clinton Health Access Initiative (CHAI) ont annoncé aujourd'hui des accords avec les sociétés pharmaceutiques Pfizer, Novartis et Mylan pour élargir l'accès à 20 traitements anticancéreux vitaux dans 26 pays d'Afrique Subsaharienne et d'Asie. Les patients devraient économiser en moyenne 59 % sur les médicaments achetés dans le cadre de ces accords.
-
The American Cancer Society (ACS) and the Clinton Health Access Initiative (CHAI) today announced agreements with pharmaceutical companies Pfizer, Novartis, and Mylan to expand access to 20 lifesaving cancer treatments in 26 countries in sub-Saharan Africa and Asia. Purchasers are expected to save an average of 59 percent for medicines procured through the agreements.
-
Today, Novartis and its partners announced the expansion of the Africa Sickle Cell Disease program to East Africa with the signature of two new memoranda of understanding with the Ministries of Health of Uganda and Tanzania.
-
Fondation Botnar and Novartis will support research capacity development in sub-Saharan Africa within the framework of EDCTP’s 2020 Career Development Fellowships.
-
The Novartis US Foundation announced that a grant provided to the New Jersey Primary Care Association (NJPCA) made it possible to launch five new telehealth programs for community health centers in the state.
-
Novartis has reached an agreement with the US Food and Drug Administration (FDA) to proceed with a Phase III clinical trial with approximately 440 patients to evaluate the use of hydroxychloroquine for the treatment of hospitalized patients with COVID-19 disease.
-
For the first time in history, the global health community is preparing to celebrate World Chagas Disease Day. Novartis is joining the global movement to raise visibility and awareness of patients with Chagas disease.
-
Novartis announced today, that in response to the COVID-19 pandemic in the US, Novartis and the Novartis US Foundation have established a US COVID-19 Community Response Fund.
-
Today, Novartis and a consortium of life sciences companies announced an important collaboration to accelerate the development, manufacture and delivery of vaccines, diagnostics, and treatments for COVID-19 in response to the pandemic.
-
Collaboration to address product development and scale up challenges posed by current pandemic SOURCE: Novartis DESCRIPTION:BASEL, Switzerland, March 26, 2020/3BL Media/ - Today, Novartis and a consortium of life sciences companies announced an important collaboration to accelerate the development, manufacture and delivery of vaccines, diagnostics, and treatments for COVID-19 in response to the pandemic. The industry brings a range of assets, resources, and expertise needed to identify effective
-
Novartis announced today its commitment to donate up to 130 million doses of generic hydroxychloroquine to support the global COVID-19 pandemic response.
-
The European & Developing Countries Clinical Trials Partnership (EDCTP) awarded a new grant to the new PAMAfrica research consortium led by Medicines for Malaria Venture (MMV).